New Reimbursement Schemes for Stratified Medicine in Oncology – A Systematic Review
نویسندگان
چکیده
منابع مشابه
Stratified Medicine and Reimbursement Issues
Stratified Medicine (SM) has the potential to target patient populations who will most benefit from a therapy while reducing unnecessary health interventions associated with side effects. The link between clinical biomarkers/diagnostics and therapies provides new opportunities for value creation to strengthen the value proposition to pricing and reimbursement (P&R) authorities. However, the int...
متن کاملTravel Medicine: A Systematic Review
Introduction: Travel medicine is devoted to the health of travelers who visit foreign countries. It is an interdisciplinary specialty concerned not only with prevention of infectious diseases during travel but also with the personal safety of travelers and the avoidance of environmental risks. Methods: This review examines 15 appropriate papers by PRISMA ...
متن کاملCROSSING THE WAY OF PRECISION MEDICINE APPROACH IN PERSONALIZED MEDICINE RESEARCH CENTER: A SYSTEMATIC REVIEW
Background: Precision medicine is a new approach in the field of medical sciences that utilizes the genetic characteristics of each patient along with clinical information to guide decisions related to diagnosis and early treatment of diseases. The Personalized Medicine Research Center, as the only center approved by the Ministry of Health, is working on precision medicine context and producing...
متن کاملCurrent issues in oncology reimbursement.
The reimbursement policies of Medicare, Medicaid, and private insurers can have a major impact on the ability of oncologists to deliver care to their patients. This article explores current issues of particular interest to oncologists, including coverage of off-label drug uses, reimbursement for drugs used in clinical trials and for costs of care for patients in trials, the effect of DRGs on th...
متن کاملStratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers
OBJECTIVES Stratified medicine is often heralded as the future of clinical practice. Key part of stratified medicine is the use of predictive biomarkers, which identify patient subgroups most likely to benefit (or least likely to experience harm) from an intervention. We investigated how many and what predictive biomarkers are currently included in European Medicines Agency (EMA) licensing. S...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.2436